Trial Profile
An Open-Label, Single Center, Nonrandomized, Phase 1 Study to Evaluate Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 11 Jul 2022 Status changed from active, no longer recruiting to completed.
- 17 Dec 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2019.
- 17 Dec 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2019.